Susanna W.L. de Geus, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreatic Neoplasms | 17 | 2023 | 5256 | 1.910 |
Why?
|
Adenocarcinoma | 13 | 2022 | 6364 | 1.470 |
Why?
|
Pancreaticoduodenectomy | 7 | 2023 | 503 | 1.460 |
Why?
|
Pancreatectomy | 6 | 2021 | 804 | 1.230 |
Why?
|
Neoadjuvant Therapy | 7 | 2023 | 2728 | 0.900 |
Why?
|
Cholecystectomy | 2 | 2021 | 395 | 0.770 |
Why?
|
Carcinoma, Hepatocellular | 5 | 2023 | 2214 | 0.690 |
Why?
|
Hepatectomy | 2 | 2023 | 550 | 0.640 |
Why?
|
Carcinoma, Pancreatic Ductal | 5 | 2023 | 1634 | 0.610 |
Why?
|
Liver Neoplasms | 5 | 2023 | 4253 | 0.540 |
Why?
|
Endarterectomy, Carotid | 1 | 2020 | 546 | 0.510 |
Why?
|
Markov Chains | 1 | 2016 | 969 | 0.440 |
Why?
|
Carotid Stenosis | 1 | 2020 | 854 | 0.440 |
Why?
|
General Surgery | 2 | 2022 | 1636 | 0.410 |
Why?
|
Propensity Score | 8 | 2023 | 1781 | 0.410 |
Why?
|
Databases, Factual | 11 | 2020 | 7729 | 0.380 |
Why?
|
Esophageal Neoplasms | 1 | 2020 | 1583 | 0.370 |
Why?
|
Gallbladder Neoplasms | 2 | 2021 | 183 | 0.350 |
Why?
|
Laparoscopy | 4 | 2023 | 2151 | 0.330 |
Why?
|
Internship and Residency | 4 | 2023 | 5788 | 0.320 |
Why?
|
Surgery, Computer-Assisted | 1 | 2016 | 1018 | 0.320 |
Why?
|
Neoplasm Staging | 9 | 2021 | 11031 | 0.310 |
Why?
|
Radiosurgery | 1 | 2017 | 1329 | 0.300 |
Why?
|
Esophagectomy | 2 | 2022 | 447 | 0.300 |
Why?
|
Retrospective Studies | 27 | 2023 | 77449 | 0.290 |
Why?
|
Lymph Node Excision | 4 | 2023 | 1261 | 0.280 |
Why?
|
Clinical Competence | 3 | 2022 | 4687 | 0.270 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2727 | 0.260 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2017 | 3479 | 0.230 |
Why?
|
Colectomy | 2 | 2019 | 683 | 0.220 |
Why?
|
Cholecystitis | 1 | 2023 | 182 | 0.220 |
Why?
|
Survival Rate | 5 | 2023 | 12788 | 0.210 |
Why?
|
Cholelithiasis | 1 | 2023 | 414 | 0.200 |
Why?
|
Treatment Outcome | 12 | 2023 | 63114 | 0.200 |
Why?
|
Breast Neoplasms, Male | 1 | 2023 | 210 | 0.200 |
Why?
|
Kaplan-Meier Estimate | 5 | 2018 | 6538 | 0.200 |
Why?
|
Leucovorin | 1 | 2023 | 628 | 0.190 |
Why?
|
Stomach Neoplasms | 2 | 2021 | 1333 | 0.190 |
Why?
|
Vascular Surgical Procedures | 2 | 2020 | 1475 | 0.190 |
Why?
|
Aged | 24 | 2023 | 163280 | 0.190 |
Why?
|
Humans | 48 | 2023 | 744343 | 0.190 |
Why?
|
Adrenal Glands | 1 | 2023 | 546 | 0.180 |
Why?
|
Peptidomimetics | 1 | 2019 | 34 | 0.180 |
Why?
|
Pancreatic Stellate Cells | 1 | 2019 | 28 | 0.170 |
Why?
|
Neoplasms | 3 | 2023 | 21683 | 0.170 |
Why?
|
United States | 17 | 2023 | 69872 | 0.160 |
Why?
|
Anastomotic Leak | 1 | 2020 | 162 | 0.160 |
Why?
|
Fluorouracil | 1 | 2023 | 1619 | 0.160 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 2019 | 230 | 0.150 |
Why?
|
Hernia, Ventral | 1 | 2020 | 176 | 0.150 |
Why?
|
Laparotomy | 1 | 2019 | 473 | 0.150 |
Why?
|
Treatment Refusal | 1 | 2020 | 421 | 0.150 |
Why?
|
Postoperative Complications | 8 | 2023 | 15295 | 0.140 |
Why?
|
Biliary Tract Surgical Procedures | 1 | 2016 | 47 | 0.140 |
Why?
|
Vascular System Injuries | 1 | 2020 | 250 | 0.140 |
Why?
|
Stents | 2 | 2020 | 3280 | 0.140 |
Why?
|
Gynecologic Surgical Procedures | 1 | 2020 | 336 | 0.140 |
Why?
|
Male | 21 | 2023 | 350118 | 0.140 |
Why?
|
Neoplasm Proteins | 2 | 2019 | 3703 | 0.130 |
Why?
|
Pelvis | 1 | 2020 | 730 | 0.130 |
Why?
|
Selection Bias | 1 | 2017 | 371 | 0.130 |
Why?
|
Female | 21 | 2023 | 380194 | 0.130 |
Why?
|
Proportional Hazards Models | 4 | 2017 | 12354 | 0.130 |
Why?
|
Colonic Diseases | 1 | 2016 | 202 | 0.130 |
Why?
|
Integrins | 1 | 2019 | 846 | 0.130 |
Why?
|
Bile Duct Diseases | 1 | 2015 | 100 | 0.130 |
Why?
|
Workload | 1 | 2020 | 850 | 0.120 |
Why?
|
Lymphatic Metastasis | 2 | 2023 | 2924 | 0.120 |
Why?
|
Middle Aged | 15 | 2021 | 213383 | 0.120 |
Why?
|
Bile Ducts | 1 | 2015 | 284 | 0.120 |
Why?
|
Pancreas | 1 | 2020 | 1686 | 0.120 |
Why?
|
Abdomen | 1 | 2020 | 1118 | 0.120 |
Why?
|
Orthopedics | 1 | 2022 | 904 | 0.110 |
Why?
|
Cholestasis | 1 | 2016 | 378 | 0.110 |
Why?
|
Hospital Mortality | 3 | 2022 | 5317 | 0.110 |
Why?
|
Survival Analysis | 4 | 2023 | 10252 | 0.110 |
Why?
|
Risk Assessment | 5 | 2020 | 23338 | 0.110 |
Why?
|
Gastric Bypass | 1 | 2021 | 812 | 0.110 |
Why?
|
Postoperative Period | 1 | 2017 | 1842 | 0.110 |
Why?
|
Pancreatitis, Chronic | 1 | 2015 | 285 | 0.100 |
Why?
|
Mammaplasty | 1 | 2022 | 1204 | 0.100 |
Why?
|
Medicare | 7 | 2023 | 6566 | 0.100 |
Why?
|
Length of Stay | 3 | 2020 | 6309 | 0.100 |
Why?
|
Education, Medical, Graduate | 2 | 2022 | 2291 | 0.100 |
Why?
|
Hospital Costs | 1 | 2018 | 985 | 0.100 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2017 | 806 | 0.090 |
Why?
|
Poverty | 1 | 2022 | 2660 | 0.090 |
Why?
|
Obesity, Morbid | 1 | 2021 | 1213 | 0.090 |
Why?
|
Bariatric Surgery | 1 | 2020 | 952 | 0.090 |
Why?
|
Digestive System Surgical Procedures | 1 | 2015 | 576 | 0.090 |
Why?
|
Life Expectancy | 1 | 2016 | 1184 | 0.090 |
Why?
|
Drainage | 1 | 2015 | 1142 | 0.090 |
Why?
|
Catheter Ablation | 1 | 2023 | 2758 | 0.090 |
Why?
|
Population Surveillance | 2 | 2022 | 2616 | 0.090 |
Why?
|
Surgical Wound Infection | 1 | 2018 | 1540 | 0.080 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12245 | 0.080 |
Why?
|
Evidence-Based Medicine | 1 | 2020 | 3610 | 0.080 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1671 | 0.070 |
Why?
|
Health Care Reform | 1 | 2016 | 1261 | 0.070 |
Why?
|
Endovascular Procedures | 1 | 2020 | 1979 | 0.070 |
Why?
|
Risk Factors | 5 | 2020 | 72290 | 0.070 |
Why?
|
Healthcare Disparities | 2 | 2023 | 3158 | 0.070 |
Why?
|
Endoscopy | 1 | 2016 | 1785 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2016 | 1956 | 0.070 |
Why?
|
Health Care Costs | 2 | 2016 | 3209 | 0.060 |
Why?
|
Breast Neoplasms | 2 | 2023 | 20822 | 0.060 |
Why?
|
Aged, 80 and over | 3 | 2020 | 57776 | 0.060 |
Why?
|
Emergency Medical Services | 1 | 2016 | 1917 | 0.060 |
Why?
|
Time Factors | 4 | 2020 | 40075 | 0.060 |
Why?
|
Registries | 1 | 2020 | 8089 | 0.060 |
Why?
|
Antineoplastic Agents | 2 | 2017 | 13695 | 0.060 |
Why?
|
Age Factors | 1 | 2020 | 18370 | 0.060 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11366 | 0.050 |
Why?
|
Hypertension | 1 | 2023 | 8480 | 0.050 |
Why?
|
Logistic Models | 4 | 2020 | 13408 | 0.050 |
Why?
|
Health Expenditures | 1 | 2015 | 2348 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2022 | 6773 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11524 | 0.050 |
Why?
|
Axilla | 1 | 2023 | 595 | 0.050 |
Why?
|
Accreditation | 1 | 2022 | 450 | 0.040 |
Why?
|
Medicaid | 2 | 2023 | 2736 | 0.040 |
Why?
|
Lymph Nodes | 2 | 2023 | 3474 | 0.040 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2023 | 709 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2015 | 39050 | 0.040 |
Why?
|
Gastrectomy | 1 | 2021 | 663 | 0.030 |
Why?
|
Cohort Studies | 4 | 2020 | 40561 | 0.030 |
Why?
|
Prospective Studies | 1 | 2020 | 53288 | 0.030 |
Why?
|
Adult | 7 | 2020 | 214055 | 0.030 |
Why?
|
Demography | 1 | 2020 | 1656 | 0.030 |
Why?
|
Deoxycytidine | 1 | 2019 | 826 | 0.030 |
Why?
|
Florida | 1 | 2016 | 435 | 0.030 |
Why?
|
Socioeconomic Factors | 2 | 2020 | 7785 | 0.030 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2020 | 719 | 0.030 |
Why?
|
Retreatment | 1 | 2016 | 610 | 0.030 |
Why?
|
Advisory Committees | 1 | 2018 | 775 | 0.030 |
Why?
|
Prognosis | 3 | 2021 | 29063 | 0.030 |
Why?
|
Mice, SCID | 1 | 2019 | 2716 | 0.030 |
Why?
|
Mastectomy | 1 | 2022 | 1793 | 0.030 |
Why?
|
Odds Ratio | 2 | 2016 | 9849 | 0.030 |
Why?
|
Patient Readmission | 2 | 2018 | 3114 | 0.030 |
Why?
|
Language | 1 | 2022 | 1471 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2022 | 1863 | 0.030 |
Why?
|
Program Evaluation | 1 | 2020 | 2488 | 0.030 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2022 | 1209 | 0.020 |
Why?
|
Neurosurgical Procedures | 1 | 2022 | 2002 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2019 | 3557 | 0.020 |
Why?
|
Reoperation | 1 | 2020 | 4201 | 0.020 |
Why?
|
Insurance Coverage | 1 | 2022 | 1901 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2016 | 3508 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2015 | 1681 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3616 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 3086 | 0.020 |
Why?
|
Curriculum | 1 | 2020 | 3605 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2017 | 2266 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6895 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8642 | 0.020 |
Why?
|
Insurance, Health | 1 | 2016 | 2494 | 0.010 |
Why?
|
Massachusetts | 1 | 2016 | 8663 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2019 | 10481 | 0.010 |
Why?
|
Patient Discharge | 1 | 2016 | 3313 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2019 | 16689 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2019 | 11483 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7279 | 0.010 |
Why?
|
Hospitalization | 1 | 2016 | 10262 | 0.010 |
Why?
|
Mice | 1 | 2019 | 81183 | 0.010 |
Why?
|
Young Adult | 1 | 2016 | 56430 | 0.010 |
Why?
|
Animals | 1 | 2019 | 168757 | 0.000 |
Why?
|